At present, the efficacy of squamous lung cancer is seldom expressed in terms of cure rate, and is generally described statistically in terms of overall survival or 5-year survival rate. The 5-year survival rate for all patients with squamous lung cancer is 12.8%, and the overall survival of advanced squamous lung cancer with chemotherapy is around 10.7 months, which means that only 50 out of 100 patients will live past about 10.7 months. For those with immune benefit, especially patients with PD-L1 ≥50%, overall survival with pembrolizumab (K-drug) monotherapy can reach 30 months. Previously, platinum-containing double agents were the gold standard of first-line treatment in advanced squamous lung cancer, and the combination of the four diamond drugs paclitaxel, doxorubicin, vincristine, gemcitabine and platinum has entered a bottleneck stage, where the median survival is hardly more than about 10.7 months. In recent years, immunotherapy and anti-angiogenic therapy for squamous lung cancer have made significant progress, and have also broken through the bottleneck that could not be overcome by previous chemotherapy, greatly extending the survival of squamous lung cancer.